webinar
Live Imaging of the Extracellular Matrix With a Glycan-Binding Fluorophore
June 9th, 2026 10:00 AM EDT
Register
Shopping Cart 0
Tel:
Email:
  1. Home
  2. Products
  3. Drug Discovery
  4. Inhibitor
  5. Other Inhibitors
  6. Tranexamic acid
Tranexamic acid
Tranexamic acid Chemical Structure

Tranexamic acid

Catalog NO.: 1197-18-8 CAS NO.: 1197-18-8 Brand: BOC Sciences

Category
Inhibitor
Targets
Other Inhibitors
Molecular Formula
C8H15NO2
Molecular Weight
157.21

Price Inquiry

WARNING: Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

cGMP Capacity

  • kg to MT scale
  • GMP batches production
  • Over 20 years of experience
  • HPAPI production with OEL < 1 μg/m³
  • Cleanroom Class 100 to Class 100,000
  • Special type of reactions in cGMP workshop
  • Cleaning level: Class A B C
  • cGMP synthesis workshop
Read More

Product Description

Tranexamic acid is a synthetic derivative of the amino acid lysine, supplied as a crystalline powder suitable for laboratory applications. Its molecular structure enables effective inhibition of plasminogen activation, making it valuable in studies of fibrinolysis and proteolytic enzyme pathways. Researchers utilize tranexamic acid to investigate protein stability and interactions under controlled biochemical conditions. The compound frequently finds application in research focused on protein engineering, peptide synthesis, and metabolic regulation.

Melting Point
>300 °C
Density
1.096 g/cm3
InChI Key
GYDJEQRTZSCIOI-UHFFFAOYSA-N
InChI
InChI=1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)
SMILES
C1CC(CCC1CN)C(=O)O
Refractive Index
1.497
Stability
Stable at room temperature in closed containers under normal storage and handling conditions.
MS
NCT NumberTitleCondition Or DiseasePhaseStart DateSponsorStatus
NCT00111215Treatment and Management of Women With Bleeding DisordersMenorrhagiaJanuary 2001Centers for Disease Control and PreventionCompleted
NCT00113568Safety Study of XP12B in Women With MenorrhagiaMenorrhagiaPhase 3June 2005Ferring PharmaceuticalsCompleted
NCT00147862Does Tranexamic Acid Administration Reduce Blood Loss During Head and Neck Surgery?Head and Neck NeoplasmsPhase 3May 2005Tata Memorial HospitalCompleted
NCT00308880Tranexamic Acid and Head and Neck Surgery PatientsHead and Neck NeoplasmsPhase 3March 2006Taichung Veterans General HospitalUnknown status
NCT00327106Tranexamic Acid in HIp Fracture Surgery (THIF Study)Hip FracturePhase 3April 2005Centre Hospitalier Universitaire de Saint EtienneCompleted
Write a review Ask a question
1.Oral surgery in liver transplant candidates: a retrospective study on delayed bleeding and other complications.
Helenius-Hietala J1, Åberg F2, Meurman JH3, Nordin A4, Isoniemi H4. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 May;121(5):490-5. doi: 10.1016/j.oooo.2016.01.025. Epub 2016 Feb 13.
OBJECTIVE: Untreated dental infections pose a threat for immunocompromised liver transplant (LT) recipients. Therefore, pretransplant dental evaluations are recommended. However, risk of bleeding should be considered among patients with end-stage liver disease, and prophylactic blood transfusions may be used to prevent bleeding. We performed a retrospective study of the incidence of and risk factors for oral surgery-related bleeding in candidates for LT and hypothesized that complications may occur despite preoperative and perioperative hemostatic actions.
2.Intravenous tranexamic acid for hyperacute primary intracerebral hemorrhage: Protocol for a randomized, placebo-controlled trial.
Sprigg N1, Robson K2, Bath P2, Dineen R2, Roberts I2, Robinson T2, Roffe C2, Werring D2, Al-Shahi Salman R2, Pocock S2, Duley L2, England T2, Whynes D2, Ciccone A2, Laska AC2, Christensen H2, Ozturk S2, Collins R2, Bereczki D2, Egea-Guerrero JJ2, Law ZK2, Int J Stroke. 2016 Apr 5. pii: 1747493016641960. [Epub ahead of print]
RATIONALE: Outcome after intracerebral hemorrhage remains poor. Tranexamic acid is easy to administer, readily available, inexpensive, and effective in other hemorrhagic conditions.
About Us

BOC Sciences is a trusted global supplier of research chemicals, biochemicals, and pharmaceutical ingredients, serving the life sciences, biotech, and pharmaceutical industries. Headquartered in New York, we offer a comprehensive product portfolio that includes inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP products, impurities and metabolites, APIs, natural compounds, ADC-related chemicals, and stem cell molecules.

We specialize in the synthesis, biosynthesis, purification, and characterization of small molecules. With years of industry experience, our scientific and technical teams support projects ranging from early discovery to process development and regulatory submission.

BOC Sciences operates GMP-compliant and ISO-certified production facilities, ensuring consistent quality and regulatory alignment. Our products and services are trusted by clients in over 60+ countries, including top pharmaceutical companies, academic institutions, and research organizations.

We are committed to providing high-quality chemicals, responsive technical support, and flexible custom solutions to accelerate innovation in drug discovery and development.

Our Clients

Online Inquiry

Basic Information
How did you hear about BOC Sciences?
Verification code